ReviewBMC infectious diseases2026
Leptomeningeal metastasis from lung adenocarcinoma associated with Lemierre syndrome in a middle-aged man: a case report and review of the literature.
Review in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLemierre syndrome (LS), predominantly triggered by oropharyngeal infection with Fusobacterium necrophorum, is a rare but life-threatening condition. The co-occurrence of LS with leptomeningeal metastases (LM) from lung adenocarcinoma (LADC) is exceptionally scarce, with only a handful of cases documented in the literature. CASE PRESENTATION: A 42-year-old male presented with neck pain and infection, which progressed to cervical venous thrombosis, cervical lymphadenopathy, and multiple pulmonary nodules, features consistent with a diagnosis of LS. The patient received targeted treatment for LS, including anticoagulation, broad-spectrum antibiotics with anaerobic coverage (piperacillin-tazobactam 4.5 g every 8 h for 2 weeks), and anti-inflammatory agents. Shortly after the successful LS treatment, the patient developed chest pain; computed tomography (CT) imaging revealed residual lung nodules, and further pathological examination confirmed LADC. He subsequently started LADC-specific therapy combining targeted agents and chemotherapy. Later, the patient reported persistent headache; enhanced brain CT confirmed LM from LADC. His treatment regimen was adjusted to include an increased dose of osimertinib.
conclusionsThis case underscores the importance of heightened clinicians’ awareness of the complex interplay between LADC leptomeningeal metastases and LS. Early recognition and multidisciplinary intervention in such multifaceted cases are crucial for optimizing patient outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.